Empagliflozin does not affect left ventricular diastolic function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial.

Keywords: Empagliflozin; SGLT2 inhibitors; Diabetes; LV diastolic function EN Empagliflozin SGLT2 inhibitors Diabetes LV diastolic function 575 578 4 03/15/22 20220401 NES 220401 Introduction Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have demonstrated promising results in reducing cardiovascular mortality and hospitalization due to heart failure (HF) in patients with type 2 diabetes mellitus (T2DM) and heart failure and reduced ejection fraction (HFrEF) [[1]]. Therefore, we sought to investigate the effect of the SGLT2i empagliflozin on LV diastolic function in patients with T2DM and coronary artery disease (CAD) using cardiac magnetic resonance imaging (CMR). Furthermore, all the patients in our trial had T2DM and CAD, whereas 35% of patients in EMPEROR Preserved trial had an ischemic cause of HF [[2], [5]]. [Extracted from the article]